Markets
PFE

Pfizer and BioNTech Complete Dosing of First Group in Coronavirus Vaccine Trial

It was just last week that Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) got permission to start a phase 1/2 clinical trial of BNT162, their SARS-CoV-2 vaccine candidate, in Germany.

Seven days later and the companies have already completed inoculating the first group of patients in the study. Of course, that group only consists of 12 participants -- and there are presumably plenty of people eager to participate given the lack of an approved coronavirus vaccine -- but the speed is still impressive nevertheless.

The safety portion of the clinical trial involves testing a range of doses from 1 microgram to 100 micrograms, and will eventually enroll 200 participants. BioNTech has developed four different variations of its mRNA vaccine. For three of the vaccines, the clinical trial will include booster shots after the initial vaccine to hopefully increase the amount of antibodies the participants generate. The fourth vaccine is a self-amplifying mRNA, so the hope is that only a single dose of the vaccine will be required.

Gloved hands giving an injection into a shoulder

Image source: Getty Images.

Pfizer licensed the rights to BioNTech's coronavirus vaccine in April for $72 million in cash and a $113 million equity investment. BioNTech is also eligible for milestone payments of up to $563 million. The companies will co-market the vaccine worldwide, except in China, where BioNTech licensed it to Fosun Pharma.

Pfizer and BioNTech expect to gain permission from the Food and Drug Administration to expand their clinical trial to the U.S. shortly. There's no word yet on a timeline for the development of the vaccine in China.

10 stocks we like better than Pfizer
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Pfizer wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of April 16, 2020

 

Brian Orelli and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

PFE BNTX

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More